In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The prevalence of chronic kidney disease and change in renal function during treatment optimization in patients with heart failure with reduced ejection fraction

Session Poster Session 2

Speaker Krisztina Kosa

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session
  • FP Number : P1066

Authors : K Kosa (Budapest,HU), B Muk (Budapest,HU), D Vagany (Budapest,HU), ZS Majoros (Budapest,HU), M Szabo (Budapest,HU), T Borsanyi (Budapest,HU), M Dekany (Budapest,HU), N Nyolczas (Budapest,HU), RG Kiss (Budapest,HU)

Authors:
K Kosa1 , B Muk1 , D Vagany1 , ZS Majoros1 , M Szabo1 , T Borsanyi1 , M Dekany1 , N Nyolczas1 , RG Kiss1 , 1Medical Centre, Hungarian Defence Forces, Cardiology - Budapest - Hungary ,

Citation:

Introduction: Optimal neurohormonal  therapy of chronic heart failure (CHF) is often complicated  by the presence of chronic kidney disease (CKD), which is an important prognostic factor of CHF.

Purpose:  We investigated the prevalence of different CKD stages and changes in renal function in the effect of treatment optimization (TO) in  patients (pts) with heart failure with reduced ejection fraction (HFrEF) followed at our heart failure outpatient clinic (HFOC).

Methods : The prevalence of different CKD stages were assessed in 469 pts with HFrEF managed at our HFOC (male:77.19%, age:62.58±12.6 years, NYHA:3.12±0.78%, LVEF:26.88±6.51%, eGFR: 51.45±19.25ml/min/1.73m2). The change in eGFR before and after TO was also determined in the whole patient group and in pts with different CKD stages.

Results: In 29.63% of pts eGFR was above 60 ml/min/1.73m2 (CKD1-2), in 59.70% was 30-60 ml/min/1.73m2 (CKD3a-3b) and in 10.66% was under 30 ml/min/1.73m2 (CKD4-5) at baseline. After TO 19.40% of pts was at CKD1-2, 63.75% at CKD3a-3b and 16.84% at CKD4-5 stage. After TO significant eGFR decrease was detected in the whole population (51.45±19.25 ? 46.03±17.09 ml/min/1.73m2; p<0.001), at baseline CKD1-2 (74.06±14.84 ? 58.81±17.29 ml/min/1.73m2; p<0.001) and baseline CKD3a-3b (45-18±8-67 ? 43-57±15-06 ml/min/1.73m2; p<0.001) pts compared to eGFR parameters before TO. Pts with CKD4-5 at baseline showed significant eGFR improvement (23.73±6,15 ? 29.78±11,37 ml/min/1.73m2; p<0.005.) Neurohormonal antagonist usage did not show significant difference after TO in pts with CKD1-2 (BB: 89.01%, ACEi/ARB: 98.90%, MRA: 57.14%), CKD3a-3b (BB: 94.31%, ACEi/ARB: 97.99%, MRA: 66.22%) and CKD4-5 (BB: 93.67%, ACEi/ARB: 94.94%, MRA: 58.23%).

Conclusions: The prevalence of CKD in HFrEF population is very high. Based on our study results renal function worsening was detected after TO in mild and moderate CKD pts, however, renal function improvement was proved in the most severe CKD4-5 pts. Our data suggests that we should strive to achieve optimal neurohormonal antagonist therapy in CKD4-5 pts too, partly because, based on previous data, the severe CKD patient group is one of the pts who benefit most from this treatment and partly because, based on our study results it seems safe treatment option in this group of patients.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are